PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
23.04%
R&D growth 50-75% of AVXL's 34.77%. Bruce Berkowitz would examine spending effectiveness.
21.61%
G&A growth while AVXL reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.65%
Similar operating expenses growth to AVXL's 21.60%. Walter Schloss would investigate norms.
22.65%
Similar total costs growth to AVXL's 21.60%. Walter Schloss would investigate norms.
No Data
No Data available this quarter, please select a different quarter.
3.49%
D&A growth less than half of AVXL's 20.51%. David Dodd would verify if efficiency is sustainable.
-23.08%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-22.65%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-58.12%
Other expenses reduction while AVXL shows 19.40% growth. Joel Greenblatt would examine advantage.
-23.20%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.20%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-16.67%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-22.50%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
5.52%
Share count reduction below 50% of AVXL's 4.23%. Michael Burry would check for concerns.
0.56%
Diluted share change of 0.56% while AVXL is stable. Bruce Berkowitz would verify approach.